Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Payables (2016 - 2025)

Iradimed (IRMD) has disclosed Payables for 13 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 66.61% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 66.61% increase, with the full-year FY2024 number at $1.9 million, down 80.71% from a year prior.
  • Payables was $2.3 million for Q3 2025 at Iradimed, up from $1.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.8 million in Q4 2023 to a low of $618217.0 in Q1 2021.
  • A 5-year average of $2.0 million and a median of $1.4 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: skyrocketed 446.49% in 2023, then crashed 80.71% in 2024.
  • Iradimed's Payables stood at $782903.0 in 2021, then soared by 129.83% to $1.8 million in 2022, then surged by 446.49% to $9.8 million in 2023, then plummeted by 80.71% to $1.9 million in 2024, then increased by 23.05% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Payables are $2.3 million (Q3 2025), $1.9 million (Q2 2025), and $2.6 million (Q1 2025).